Evidence Repository
The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!

Variant: NM_006767.4(LZTR1):c.1234C>T (p.Arg412Cys)

CA501019

373089 (ClinVar)

Gene: LZTR1
Condition: RASopathy
Inheritance Mode: Autosomal dominant inheritance
Link to MONDO
UUID: c382a894-de4a-4be7-85f1-8003be6e6f47
Approved on: 2024-09-17
Published on: 2024-09-30

HGVS expressions

NM_006767.4:c.1234C>T
NM_006767.4(LZTR1):c.1234C>T (p.Arg412Cys)
NC_000022.11:g.20992878C>T
CM000684.2:g.20992878C>T
NC_000022.10:g.21347167C>T
CM000684.1:g.21347167C>T
NC_000022.9:g.19677167C>T
NG_034193.1:g.15610C>T
ENST00000700578.1:c.1234C>T
ENST00000495142.6:n.579C>T
ENST00000642151.1:c.1065C>T
ENST00000643578.1:n.1256C>T
ENST00000646124.2:c.1234C>T
ENST00000646506.1:n.813C>T
ENST00000215739.12:c.1234C>T
ENST00000479606.5:n.1380C>T
ENST00000492480.1:n.290C>T
NM_006767.3:c.1234C>T
More

Uncertain Significance

Met criteria codes 1
PS4_Supporting
Not Met criteria codes 5
BS1 BP4 BA1 PP3 PM2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for LZTR1 Version 1.1.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
RASopathy VCEP
The NM_006767.4:c.1234C>T (p.Arg412Cys) variant in LZTR1 is a missense variant predicted to cause substitution of arginine by cysteine at amino acid 412. Evidence supports that this variant is associated with AD NS and is not associated with AR NS. The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003850 (1/25972 alleles) in the Ashkenazi Jewish population (PM2_Supporting, BS1, and BA1 are not met). The computational predictor REVEL gives a score of 0.351, which is neither above nor below the thresholds predicting a damaging or benign impact on LZTR1 function. This variant has been reported in 1 proband with features of RASopathy (PS4_Supporting; PMID:32981126). Schwannomatosis has not been observed in individuals harboring this variant. In summary, this variant meets the criteria to be classified as uncertain significance for autosomal dominant RASopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy VCEP: PS4_Supporting. (RASopathy VCEP specifications version 1.1; 9/17/2024)
Met criteria codes
PS4_Supporting
This variant has been reported in 1 proband with features of RASopathy (PS4_Supporting; PMID:32981126).
Not Met criteria codes
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3
The computational predictor REVEL gives a score of 0.351, which is neither above nor below the thresholds predicting a damaging or benign impact on LZTR1 function.
PM2
The highest population minor allele frequency in gnomAD v2.1.1 is 0.00003850 (1/25972 alleles) in the Ashkenazi Jewish population (PM2_Supporting, BS1, and BA1 are not met).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.